President, Clinical Diagnostics · Natera, Inc. (NTRA)

Solomon Moshkevich

A named executive officer of Natera in every fiscal year CompBrief holds from FY2024 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$5,367,000

FY2024: $4,888,856

Compensation figures as of the proxy filed April 23, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-09-24.

Solomon Moshkevich compensation by year

Natera Summary Compensation Table · all 2 fiscal years held
In US dollars, as Natera reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024FY2025
Salary$490,032$504,652
Bonus$0$0
Stock awards$4,103,350$4,500,844
Option awards$0$0
Non-equity incentive$285,574$351,604
Pension and deferred compensation—$0
All other$9,900$9,900
Total$4,888,856$5,367,000

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Natera, Inc. DEF 14A filed April 23, 2026, accession 0001104659-26-047770, and prior-year filings. Open the filing on EDGAR.

$4.9M
$5.4M
FY24
FY25
SalaryNon-equity incentiveStock awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU44,698$10,239,865—
PSU31,352$7,182,430—
RSU29,423$6,740,515—
RSU17,636$4,040,231—
PSU12,720$2,914,025—
RSU12,720$2,914,025—
RSU11,640$2,666,608—
RSU3,206$734,463—
RSU571$130,810—
Option34,000—$19.68
Option5,932—$15.57
Option5,125—$9.59

Per the Outstanding Equity Awards at Fiscal Year-End table in Natera, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 14 award rows shown.

Insider transactions since the last proxy

31 Form 4 lines since the FY2025 proxy (filed April 23, 2026)
current to 2026-09-24 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-09-16Gift—945$0.00109,914
2026-09-02Sale10b5-115,160$326.89110,859
2026-09-01Sale10b5-11,000$319.76128,019
2026-09-01Sale10b5-11,400$320.92126,619
2026-09-01Sale10b5-1600$321.91126,019
2026-08-03Sale10b5-1947$263.94130,572
2026-08-03Sale10b5-1300$259.98131,719
2026-08-03Sale10b5-1410$267.99132,019

The 8 most recent of 31 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Change-in-control & termination

estimated payments Natera discloses, by trigger · FY2025
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Change in control and involuntary termination$503,920$27,323,106$35,027$27,862,053
Involuntary termination without cause$251,960$28,504,294$35,027$28,791,281
Change in control, no termination$0$10,239,865$0$10,239,865

Per the Potential Payments Upon Termination or Change in Control table in Natera, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.

Natera’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Steven ChapmanChief Executive Officer, President and Director$14,957,319
Matthew RabinowitzExecutive Chairman$11,283,382
Michael BrophyChief Financial Officer$5,460,022
Solomon Moshkevich · this pagePresident, Clinical Diagnostics$5,367,000
John FeskoPresident, Chief Business Officer$5,052,790

The full Natera compensation record

free company brief

This page is one person within Natera's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Natera's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Natera's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy